SAB Biotherapeutics (SABS)
NASDAQ:SABS
Top Page
SAB Biotherapeutics
(NASDAQ:SABS)
Select Model
Select Model
Rating:50Neutral
Price Target:
$3.50
▼(-6.17% Downside)
Action:ReiteratedDate:03/20/26
The score is held back primarily by weak financial performance (revenue collapse, sustained operating losses, and ongoing cash burn). Corporate updates and financing improve runway and support pipeline progress, while technicals are only modest and valuation appears low on P/E but lacks dividend support and is tempered by fundamental risk.
Positive Factors
Proprietary Tc Bovine antibody platform
SAB's Tc Bovine platform is a durable technological moat: it enables production of fully human polyclonal antibodies at scale, supporting multi-target therapeutics. This platform differentiation underpins long-term R&D optionality across infectious and autoimmune indications and potential partner interest.
Negative Factors
Revenue collapse and multi-year operating losses
A structural absence of revenue and sustained operating losses mean core commercial capability is unproven; the firm's economic model remains dependent on clinical success and external funding. This persistent lack of operating cash generation weakens resilience to clinical setbacks and lengthens time-to-profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Tc Bovine antibody platform
SAB's Tc Bovine platform is a durable technological moat: it enables production of fully human polyclonal antibodies at scale, supporting multi-target therapeutics. This platform differentiation underpins long-term R&D optionality across infectious and autoimmune indications and potential partner interest.
Read all positive factors
SAB Biotherapeutics (SABS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$195.14M
Dividend YieldN/A
Average Volume (3M)398.22K
Price to Earnings (P/E)5.4
Beta (1Y)0.87
Revenue Growth-92.42%
EPS Growth62.37%
CountryUS
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding50,951,040
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.24
Enterprise Value/Ebitda1.93
Forecast
1Y Price Target
$10.50Price Target Upside181.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
SAB Biotherapeutics Business Overview & Revenue Model
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine her...
How the Company Makes Money
null...
SAB Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 1.32M | 2.24M | 23.90M | 60.88M |
| Gross Profit | -3.08M | -3.47M | -1.51M | 20.61M | 59.22M |
| EBITDA | 16.60M | -28.99M | -38.13M | -15.12M | -15.20M |
| Net Income | 13.27M | -34.11M | -42.19M | -18.74M | -17.14M |
Balance Sheet | |||||
| Total Assets | 172.81M | 44.20M | 83.94M | 50.90M | 81.14M |
| Cash, Cash Equivalents and Short-Term Investments | 96.59M | 20.76M | 56.57M | 15.05M | 33.21M |
| Total Debt | 5.95M | 4.67M | 5.91M | 5.93M | 8.52M |
| Total Liabilities | 21.32M | 18.23M | 26.64M | 19.85M | 42.59M |
| Stockholders Equity | 151.49M | 25.97M | 57.30M | 31.06M | 38.55M |
Cash Flow | |||||
| Free Cash Flow | -45.71M | -34.63M | -25.32M | -25.63M | -8.96M |
| Operating Cash Flow | -44.78M | -34.29M | -25.12M | -23.46M | 1.99M |
| Investing Cash Flow | -121.71M | -11.96M | -152.70K | -2.09M | -10.94M |
| Financing Cash Flow | 168.30M | -1.17M | 66.77M | 1.05M | 35.89M |
SAB Biotherapeutics Technical Analysis
Negative
3.73
Price Trends
4.00
Negative
3.91
Negative
3.14
Positive
Market Momentum
-0.05
Positive
43.24
Neutral
24.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Negative. The current price of 3.73 is below the 20-day moving average (MA) of 3.93, below the 50-day MA of 4.00, and above the 200-day MA of 3.14, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 24.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SABS.
SAB Biotherapeutics Risk Analysis
SAB Biotherapeutics disclosed 80 risk factors in its most recent earnings report. SAB Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SAB Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $43.43M | -3.44 | -16.25% | ― | 12.71% | 79.93% | |
59 Neutral | $45.16M | -0.97 | -84.39% | ― | ― | 15.32% | |
54 Neutral | $39.91M | -0.72 | -152.90% | ― | ― | 3.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $195.14M | 5.44 | -21.16% | ― | -92.42% | 62.37% | |
46 Neutral | $40.92M | -0.71 | -80.00% | ― | ― | 9.63% |
* Healthcare Sector Average
SABS
SAB Biotherapeutics
3.83
2.65
224.58%
LSTA
Lisata Therapeutics
5.00
3.05
156.28%
NXTC
NextCure
11.21
7.97
245.99%
SNSE
Sensei Biotherapeutics
30.53
24.22
383.53%
RLYB
Rallybio
8.21
6.21
309.68%
SAB Biotherapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
SAB Biotherapeutics Launches Major Equity Financing Offering
Positive
Mar 19, 2026
On March 17, 2026, SAB Biotherapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 additional shares, all sold by the company at ...
Business Operations and StrategyProduct-Related Announcements
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
Positive
Mar 10, 2026
On March 10, 2026, SAB Biotherapeutics, Inc. reported additional Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established autoimmune type 1 diabetes. The company simultaneously made a detailed data pres...
Business Operations and StrategyFinancial Disclosures
SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook
Positive
Jan 12, 2026
On January 12, 2026, SAB Biotherapeutics posted an updated corporate presentation outlining strong 2025 execution and a multi‑year clinical and financial roadmap centered on SAB‑142 for newly diagnosed Stage 3 Type 1 diabetes. The comp...
Business Operations and StrategyExecutive/Board Changes
SAB Biotherapeutics Appoints New Independent Board Chair, Directors
Positive
Jan 7, 2026
On January 5, 2026, SAB Biotherapeutics appointed veteran biopharma executive David Zaccardelli, Pharm.D., and rheumatologist and drug development leader Rita Jain, M.D., as Class II directors, with Zaccardelli becoming Chair of the Board and both...
Business Operations and StrategyPrivate Placements and Financing
SAB Biotherapeutics Launches New $75 Million ATM Program
Positive
Dec 29, 2025
On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with UBS Securities LLC to establish an at-the-market equity offering program allowing the company to issue and sell up to $75 million of its common stock from time...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.